ECCO 2019: Vedolizumab and anti-TNF in Crohn’s disease are equally effective

In this MEDtalk Brian Bressler present data from a multi-country, retrospective chart review study assessed the effectiveness and safety of vedolizumab compared with anti-tumour necrosis factors  agents in a real-world cohort of biologic-naïve Crohn’s disease patients.